b02dc7a2-3615-4b6c-a3dd-a866d8561d9d
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 69
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.540
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.520
- IL6_JAK_STAT3_SIGNALING+0.500
- INTERFERON_GAMMA_RESPONSE+0.490
- ANGIOGENESIS+0.480
- INFLAMMATORY_RESPONSE+0.480
- INTERFERON_ALPHA_RESPONSE+0.470
- HEDGEHOG_SIGNALING+0.420
- TNFA_SIGNALING_VIA_NFKB+0.420
- KRAS_SIGNALING_UP+0.360
Top 10 suppressed
- DNA_REPAIR-0.440
- MYC_TARGETS_V1-0.440
- E2F_TARGETS-0.410
- OXIDATIVE_PHOSPHORYLATION-0.390
- G2M_CHECKPOINT-0.330
- FATTY_ACID_METABOLISM-0.300
- MYC_TARGETS_V2-0.280
- UNFOLDED_PROTEIN_RESPONSE-0.280
- MTORC1_SIGNALING-0.260
- PANCREAS_BETA_CELLS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CR-7376-01A-11R-2132-07 | — | — | 0.949 |
| 2 | f22cfa82-a346-4fed-bc81-21a29bf990ee | — | — | 0.942 |
| 3 | TCGA-CV-6943-01A-11R-1915-07 | — | — | 0.937 |
| 4 | TCGA-A2-A0YD-01A-11R-A109-07 | — | A | 0.936 |
| 5 | cadbc884-10b6-41e4-8aee-dc11a1453b8c | — | — | 0.935 |
| 6 | C3N-02923 | — | cohortMD2 | 0.935 |
| 7 | TCGA-D8-A141-01A-11R-A115-07 | — | A | 0.933 |
| 8 | ec054d40-e5b8-496a-8c99-5e7f88f2cf37 | — | — | 0.930 |
| 9 | MDT-AP-3277 | Med | Medulloblastoma | 0.928 |
| 10 | TCGA-85-6175-01A-11R-1820-07 | — | cohortSQ1 | 0.928 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.540 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.520 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.480 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.480 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.420 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.420 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.360 | Inavolisib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.340 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.320 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.310 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.270 | Temsirolimus | — uncovered |
| COAGULATION | 0.240 | Binimetinib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |